Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.
Deregulating New Zealand's gene tech space has been long-desired, but critics say the Government's growth-focused approach ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a ...
We tested eight popular home tool kits to see how they compared in functionality, design and overall usefulness. Two came out ...
has developed a urine-based diagnostic kit for bladder cancer that can be conveniently used at home. This kit can accurately detect bladder cancer biomarkers without any preprocessing of urine ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says the company is the “pioneer of gene editing” and ...
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...